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WS8.1 The role of second-generation sequencing in describing the
fungal microbiota in the adult cystic ﬁbrosis (CF) airway and
its correlation with clinical phenotype
M.J. Harrison1,2, K.B. Twomey3, Y. McCarthy3, O.J. O’Connell1, M. Alston4,
M. Febrer4, D.M. Murphy1,2, J.A. Eustace2, B.J. Plant1,2. 1Cork Adult Cystic
Fibrosis Centre, Cork University Hospital, Dept of Respiratory Medicine, Cork,
Ireland; 2HRB Clinical Research Facility, University College Cork, Cork, Ireland;
3BIOMERIT Research Centre, Biosciences Institute, University College Cork,
Department of Microbiology, Cork, Ireland; 4The Genome Analysis Centre,
Norwich Research Park, Norwich, United Kingdom
Objectives: The clinical role of fungus in the CF airway is uncertain. This study
examines the fungal microbiota of the CF airway using a bar-coded high-throughput
sequencing (HTS) method, and correlates with standard culture-based methods and
clinical phenotype including FEV1% predicted, genotype, gender, and BMI.
Methods: Sputa from 59 stable adult CF and 5 non-CF bronchiectasis patients were
prospectively analysed.
Conclusion: Culture-based methods detected fungus (Aspergillus spp. and Candida
spp. only) in 25% (n = 15/59) of patients. HTS with subsequent quantitative RT-PCR
identiﬁed fungus in all samples, with a signiﬁcantly greater abundance of fungus
in the CF group (106 copies/ml) versus the non-CF controls (101 copies/ml). HTS
revealed a complex fungal community in the stable CF airway with only 18% of
species identiﬁed using culture-based methods. Correlating clinical phenotype with
fungal microbiota diversity and species richness using multivariate linear regression
revealed an inverse correlation between the abundance of Malassezia spp and
lung function (R2 = 0.181, p = 0.04). There was also a trend towards a positive
relationship between the abundance of Eleutheromyces spp. and lung function
(p = 0.83). No further association between the abundance of other fungal genera
and clinical phenotype was seen. This study comprehensively examines fungal
community dynamics in the CF airway. HTS methods highlight an unappreciated
potential role of previously difﬁcult to culture fungal strains like Malassezia spp
within the CF airway. Understanding the clinical signiﬁcance of fungal microbiota
composition, diversity and richness may provide additional therapeutic targets.
WS8.2 Effect of Staphylococcus aureus on the outcome of pulmonary
Pseudomonas aeruginosa infection in a murine model
A. Monahan1, R. Ryan2, J.S. Elborn1, R. Ingram1. 1Queen’s University, Centre
for Infection and Immunity, Belfast, United Kingdom; 2University College Cork,
Cork, Ireland
Previous studies have suggested that anti-staphylococcal therapy in young cystic
ﬁbrosis patients may favour early pulmonary colonisation with P. aeruginosa.
Objectives: This study examined the effect that colonisation of murine lungs with
clinical isolates of S. aureus has on the outcome of P. aeruginosa infection.
Methods and Results: Groups of outbred mice (CD1) were either infected
intranasally with a sub-lethal dose of various clinical isolates of S. aureus or given
sham/PBS. Mice we allowed to recover and 12 days later were inoculated with
P. aeruginosa intranasally. Mice which had administered Q154, a clinical isolate
originating from the sputum of a chronically infected CF patient, had improved
survival rates compared to mice which had been given Q181, an isolate which had
previously caused toxic shock in a CF patient. Subsequent analysis of these two
S. aureus strains revealed that they both had similar antibiotic susceptibility proﬁles
and both were virulent strains in a moth larvae model of infection. Q154 produced
protease in vitro whereas Q181 did not. Furthermore, Q154 also had an increased
ability to produce bioﬁlm in vitro. The lung cellular inﬁltrate and inﬂammatory
cytokine proﬁle have been characterised after infection with these two S. aureus
isolates in order to gain further insight into the divergent impact of these two
isolates.
Conclusions: Based on these results it is evident that S. aureus is able to modulate
the outcome of P. aeruginosa infection in a murine model, with the impact being
dependent on the S. aureus isolate. The mechanism for this diversity of inﬂuence
remains to be elucidated.
WS8.3 Cystic ﬁbrosis transmembrane conductance regulator (CFTR)
allelic variants relate to shifts in fecal microbiota of cystic
ﬁbrosis patients
V. Iebba1, F. Santangelo1, R.V. De Biase1, A. Stamato1, S. Bertasi1, D. Savi1,
M. Lucarelli1, M.P. Conte1, S. Schippa1, S. Quattrucci1. 1‘Sapienza’ University of
Rome, Rome, Italy
Objectives: The human gastrointestinal tract is inhabited by a very diverse sym-
biotic microbiota, the composition of which depends on host genetics and the
environment. The aim of the study was to investigate how CFTR gene variants
could be related to fecal microbiota composition in cystic ﬁbrosis (CF) patients.
Around 1500 mutations and 300 polymorphisms of this gene are known, usually
divided into ﬁve classes of severity.
Methods: CFTR genetic background was assessed in 36 CF patients, and fecal
microbiota was investigated by TTGE ﬁngerprinting technique and species-speciﬁc
PCR. Multivariate statistical analyses were employed.
Conclusion: In an exploratory analysis we showed, through microbiota ﬁngerprint-
ing experiments, how severe CF patients withsevere CFTR mutations (e.g. F508del)
harbor a different fecal microbiota structure than mild patients. We also showed, by
species-speciﬁc PCR, how particular bacterial species are related to mild or severe
clinical manifestations and to genetic background. Presence and relative abundance
of Eubacterium biforme and Escherichia coli species were related to severe CFTR
alleles, whilst Eubacterium limosum and Fecalibacterium prausnitzii species were
related to the mild one. This is the ﬁrst report that establishes a link between
CFTR allelic variants and the corresponding shifts in fecal microbiota, opening the
way to studies aimed at discovering possibly new bacterial markers in CF patients,
depending on disease severity.
WS8.4 Temporal bacterial community dynamics of cystic ﬁbrosis
lung infections
L. Cuthbertson1,2, G.B. Rogers2, A.W. Walker3, A. Oliver1, T. Daniels4,
M.P. Carroll4, J. Parkhill3, K.D. Bruce2, C.J. van der Gast1. 1NERC Centre
for Ecology and Hydrology, Maclean Building, Wallingford, United Kingdom;
2King’s College London, Molecular Microbiology Research Laboratory, London,
United Kingdom; 3Wellcome Trust Sanger Institute, Cambridge, United Kingdom;
4Southampton University Hospitals, Cystic Fibrosis Unit, Southampton, United
Kingdom
Objectives: Chronic lung infections are the biggest cause of morbidity and mortality
of patients suffering from cystic ﬁbrosis (CF). In recent years molecular based,
cross-sectional studies of CF microbial ecology have identiﬁed a diverse and highly
variable microbial community within the CF lung. Although these studies have
provided useful insights into CF lung community ecology they have provided little
information about community dynamics over time, during periods of both disease
stability and exacerbation.
Methods: Fourteen patients attending the Southampton general hospital CF clinic
provided sputum samples over the course of a year. DNA was extracted from these
samples and analysed by directed 454 high-throughput pyrosequencing. Statistical
analyses were carried out within an ecological framework to examine how the
bacterial community within the CF lung changes over time, in the context of relevant
clinical metadata.
Conclusion:We observed that during periods of stability the rate of bacterial species
turnover (immigrations and extinctions) was also stable. However, leading into
periods of clinical exacerbation, rates of turnover became high, mirroring worsening
lung function. These changes were not confounded by intravenous (IV) antibiotic
administration; where IV antibiotics are given once a patient is clinically judged to
be in a period of exacerbation.
Our results suggest that the microbiota is changing before the introduction of IV
antibiotics and these changes may serve as marker of disease severity with future
implications for management of CF lung infections.
